Viatris Inc. (VTRS)
USD 7.52
(3.51%)
USD 7.52
(3.51%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 17.13 Billion USD | -4.86% |
| 2022 | 18 Billion USD | -19.51% |
| 2021 | 22.36 Billion USD | -10.5% |
| 2020 | 24.99 Billion USD | 104.93% |
| 2019 | 12.19 Billion USD | -9.19% |
| 2018 | 13.43 Billion USD | -6.53% |
| 2017 | 14.36 Billion USD | -0.72% |
| 2016 | 14.47 Billion USD | 138.44% |
| 2015 | 6.07 Billion USD | -26.5% |
| 2014 | 8.25 Billion USD | 6.56% |
| 2013 | 7.75 Billion USD | 44.04% |
| 2012 | 5.38 Billion USD | 9.55% |
| 2011 | 4.91 Billion USD | 3.53% |
| 2010 | 4.74 Billion USD | -0.05% |
| 2009 | 4.74 Billion USD | 2.4% |
| 2008 | 4.63 Billion USD | -2.86% |
| 2007 | 4.77 Billion USD | 0.0% |
| 2006 | 539.4 Million USD | 561.73% |
| 2005 | 539.4 Million USD | 491.63% |
| 2004 | -137.73 Million USD | -35.41% |
| 2003 | -101.71 Million USD | 0.0% |
| 2002 | -138.92 Million USD | 30.75% |
| 2001 | -200.59 Million USD | -23.07% |
| 2000 | -162.98 Million USD | -11.56% |
| 1999 | -146.1 Million USD | -111.43% |
| 1998 | -69.1 Million USD | 9.2% |
| 1997 | -76.1 Million USD | 51.71% |
| 1996 | -157.6 Million USD | -31.11% |
| 1995 | -120.2 Million USD | -69.53% |
| 1994 | -70.9 Million USD | 23.85% |
| 1993 | -93.1 Million USD | -64.2% |
| 1992 | -56.7 Million USD | -60.17% |
| 1991 | -35.4 Million USD | -71.01% |
| 1990 | -20.7 Million USD | 29.35% |
| 1989 | -29.3 Million USD | -1.38% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 16.17 Billion USD | -4.56% |
| 2024 Q1 | 16.94 Billion USD | -1.07% |
| 2023 FY | 17.38 Billion USD | -3.49% |
| 2023 Q4 | 17.13 Billion USD | 0.38% |
| 2023 Q3 | 17.06 Billion USD | -5.05% |
| 2023 Q1 | 18.26 Billion USD | 1.45% |
| 2023 Q2 | 17.97 Billion USD | -1.6% |
| 2022 Q4 | 18 Billion USD | -6.87% |
| 2022 FY | 18.01 Billion USD | -13.78% |
| 2022 Q1 | 21.26 Billion USD | -4.95% |
| 2022 Q2 | 20.32 Billion USD | -4.43% |
| 2022 Q3 | 19.33 Billion USD | -4.86% |
| 2021 Q2 | 23.69 Billion USD | 0.44% |
| 2021 Q3 | 22.68 Billion USD | -4.25% |
| 2021 Q4 | 22.36 Billion USD | -1.39% |
| 2021 FY | 20.89 Billion USD | -17.3% |
| 2021 Q1 | 23.58 Billion USD | -5.43% |
| 2020 Q1 | 12.05 Billion USD | -1.12% |
| 2020 Q2 | 11.81 Billion USD | -2.02% |
| 2020 Q3 | 11.61 Billion USD | -1.65% |
| 2020 Q4 | 24.94 Billion USD | 114.65% |
| 2020 FY | 25.26 Billion USD | 106.29% |
| 2019 Q3 | 12.65 Billion USD | -3.23% |
| 2019 Q4 | 12.19 Billion USD | -3.63% |
| 2019 Q1 | 13.51 Billion USD | 0.61% |
| 2019 FY | 12.24 Billion USD | -9.1% |
| 2019 Q2 | 13.07 Billion USD | -3.21% |
| 2018 Q2 | 14.35 Billion USD | -2.36% |
| 2018 FY | 13.47 Billion USD | -6.32% |
| 2018 Q4 | 13.43 Billion USD | -4.0% |
| 2018 Q3 | 13.98 Billion USD | -2.56% |
| 2018 Q1 | 14.7 Billion USD | 2.34% |
| 2017 Q3 | 14.1 Billion USD | -1.93% |
| 2017 FY | 14.38 Billion USD | -0.77% |
| 2017 Q4 | 14.36 Billion USD | 1.9% |
| 2017 Q2 | 14.37 Billion USD | 1.0% |
| 2017 Q1 | 14.23 Billion USD | -1.65% |
| 2016 Q4 | 14.47 Billion USD | 0.47% |
| 2016 Q2 | 6.96 Billion USD | 11.27% |
| 2016 Q3 | 14.4 Billion USD | 106.75% |
| 2016 FY | 14.49 Billion USD | 186.47% |
| 2016 Q1 | 6.26 Billion USD | 3.17% |
| 2015 Q3 | 5.84 Billion USD | -27.76% |
| 2015 Q1 | 8.35 Billion USD | 1.16% |
| 2015 Q2 | 8.09 Billion USD | -3.12% |
| 2015 Q4 | 6.07 Billion USD | 3.81% |
| 2015 FY | 5.05 Billion USD | -8.13% |
| 2014 Q2 | 8.03 Billion USD | 1.54% |
| 2014 Q4 | 8.25 Billion USD | 5.58% |
| 2014 Q1 | 7.9 Billion USD | 2.03% |
| 2014 Q3 | 7.82 Billion USD | -2.59% |
| 2014 FY | 5.5 Billion USD | -28.83% |
| 2013 FY | 7.73 Billion USD | 55.17% |
| 2013 Q1 | 5.37 Billion USD | 7.83% |
| 2013 Q2 | 5.94 Billion USD | 10.51% |
| 2013 Q4 | 7.75 Billion USD | 30.24% |
| 2013 Q3 | 5.95 Billion USD | 0.0% |
| 2012 FY | 4.98 Billion USD | 1.29% |
| 2012 Q2 | 5.74 Billion USD | 23.53% |
| 2012 Q1 | 4.64 Billion USD | -5.59% |
| 2012 Q3 | 5.02 Billion USD | -12.41% |
| 2012 Q4 | 4.98 Billion USD | -0.84% |
| 2011 Q3 | 4.83 Billion USD | -7.43% |
| 2011 Q1 | 4.93 Billion USD | 3.35% |
| 2011 FY | 4.92 Billion USD | 7.01% |
| 2011 Q4 | 4.92 Billion USD | 1.92% |
| 2011 Q2 | 5.21 Billion USD | 5.83% |
| 2010 Q4 | 4.77 Billion USD | 3.69% |
| 2010 FY | 4.6 Billion USD | -0.07% |
| 2010 Q3 | 4.6 Billion USD | 8.57% |
| 2010 Q2 | 4.23 Billion USD | -6.57% |
| 2010 Q1 | 4.53 Billion USD | -5.47% |
| 2009 Q2 | 4.54 Billion USD | 0.83% |
| 2009 Q1 | 4.51 Billion USD | -5.31% |
| 2009 FY | 4.6 Billion USD | -0.08% |
| 2009 Q4 | 4.79 Billion USD | 5.59% |
| 2009 Q3 | 4.54 Billion USD | -0.1% |
| 2008 Q4 | 4.76 Billion USD | 4.6% |
| 2008 Q2 | 5.05 Billion USD | 4.53% |
| 2008 Q1 | 4.83 Billion USD | 0.0% |
| 2008 FY | 4.6 Billion USD | -7.55% |
| 2008 Q3 | 4.55 Billion USD | -9.95% |
| 2007 Q2 | 578.57 Million USD | -8.97% |
| 2007 FY | 4.98 Billion USD | 824.08% |
| 2007 Q1 | 635.6 Million USD | 57.56% |
| 2007 Q3 | 486.2 Million USD | -15.97% |
| 2006 Q1 | 539.4 Million USD | -10.83% |
| 2006 Q2 | 535.12 Million USD | -0.79% |
| 2006 Q3 | 527.21 Million USD | -1.48% |
| 2006 Q4 | 403.41 Million USD | -23.48% |
| 2006 FY | 539.4 Million USD | 561.73% |
| 2005 Q1 | -116.82 Million USD | 29.01% |
| 2005 FY | -116.82 Million USD | -44.23% |
| 2005 Q2 | -276.22 Million USD | -136.45% |
| 2005 Q3 | 614.19 Million USD | 322.35% |
| 2005 Q4 | 604.88 Million USD | -1.52% |
| 2004 Q1 | -80.99 Million USD | 26.98% |
| 2004 Q4 | -164.56 Million USD | -50.49% |
| 2004 Q3 | -109.35 Million USD | 30.03% |
| 2004 FY | -80.99 Million USD | 65.88% |
| 2004 Q2 | -156.28 Million USD | -92.96% |
| 2003 Q4 | -110.92 Million USD | 36.27% |
| 2003 Q2 | -188.05 Million USD | 20.78% |
| 2003 Q1 | -237.37 Million USD | -2.05% |
| 2003 FY | -237.37 Million USD | -70.87% |
| 2003 Q3 | -174.06 Million USD | 7.44% |
| 2002 Q4 | -232.6 Million USD | -19.82% |
| 2002 Q3 | -194.12 Million USD | -197.54% |
| 2002 Q2 | -65.24 Million USD | 53.03% |
| 2002 FY | -138.92 Million USD | 30.75% |
| 2002 Q1 | -138.92 Million USD | -10.12% |
| 2001 Q2 | -156.42 Million USD | 22.02% |
| 2001 FY | -200.59 Million USD | -23.07% |
| 2001 Q4 | -126.15 Million USD | 26.13% |
| 2001 Q3 | -170.78 Million USD | -9.18% |
| 2001 Q1 | -200.59 Million USD | -14.44% |
| 2000 Q1 | -162.98 Million USD | 17.47% |
| 2000 Q3 | -180.88 Million USD | -28.7% |
| 2000 FY | -162.98 Million USD | -11.56% |
| 2000 Q4 | -175.28 Million USD | 3.09% |
| 2000 Q2 | -140.55 Million USD | 13.77% |
| 1999 Q1 | -146.1 Million USD | -1.88% |
| 1999 Q2 | -162.1 Million USD | -10.95% |
| 1999 Q3 | -193.3 Million USD | -19.25% |
| 1999 FY | -146.1 Million USD | -111.43% |
| 1999 Q4 | -197.5 Million USD | -2.17% |
| 1998 Q2 | -103.6 Million USD | -49.93% |
| 1998 Q1 | -69.1 Million USD | -3.44% |
| 1998 Q3 | -112.5 Million USD | -8.59% |
| 1998 Q4 | -143.4 Million USD | -27.47% |
| 1998 FY | -69.1 Million USD | 9.2% |
| 1997 Q3 | -42.1 Million USD | 27.16% |
| 1997 Q4 | -66.8 Million USD | -58.67% |
| 1997 Q1 | -76.1 Million USD | 9.73% |
| 1997 FY | -76.1 Million USD | 51.71% |
| 1997 Q2 | -57.8 Million USD | 24.05% |
| 1996 Q1 | -157.6 Million USD | 13.55% |
| 1996 Q4 | -84.3 Million USD | -4.85% |
| 1996 Q3 | -80.4 Million USD | 51.83% |
| 1996 Q2 | -166.9 Million USD | -5.9% |
| 1996 FY | -157.6 Million USD | -31.11% |
| 1995 FY | -120.2 Million USD | -69.53% |
| 1995 Q2 | -134 Million USD | -11.48% |
| 1995 Q1 | -120.2 Million USD | 17.61% |
| 1995 Q4 | -182.3 Million USD | -27.3% |
| 1995 Q3 | -143.2 Million USD | -6.87% |
| 1994 Q3 | -123.3 Million USD | -57.27% |
| 1994 Q1 | -70.9 Million USD | 28.09% |
| 1994 Q2 | -78.4 Million USD | -10.58% |
| 1994 Q4 | -145.9 Million USD | -18.33% |
| 1994 FY | -70.9 Million USD | 23.85% |
| 1993 Q1 | -93.1 Million USD | -10.05% |
| 1993 Q3 | -90.3 Million USD | 2.38% |
| 1993 FY | -93.1 Million USD | -64.2% |
| 1993 Q2 | -92.5 Million USD | 0.64% |
| 1993 Q4 | -98.6 Million USD | -9.19% |
| 1992 Q1 | -56.7 Million USD | -30.34% |
| 1992 Q3 | -60.9 Million USD | -8.56% |
| 1992 Q2 | -56.1 Million USD | 1.06% |
| 1992 Q4 | -84.6 Million USD | -38.92% |
| 1992 FY | -56.7 Million USD | -60.17% |
| 1991 Q4 | -43.5 Million USD | -8.21% |
| 1991 Q3 | -40.2 Million USD | -11.05% |
| 1991 FY | -35.4 Million USD | -71.01% |
| 1991 Q2 | -36.2 Million USD | -2.26% |
| 1991 Q1 | -35.4 Million USD | -21.65% |
| 1990 Q2 | -27.2 Million USD | -31.4% |
| 1990 Q3 | -38.1 Million USD | -40.07% |
| 1990 Q4 | -29.1 Million USD | 23.62% |
| 1990 FY | -20.7 Million USD | 29.35% |
| 1990 Q1 | -20.7 Million USD | 5.91% |
| 1989 Q1 | -29.3 Million USD | 0.0% |
| 1989 Q4 | -22 Million USD | -16.4% |
| 1989 Q3 | -18.9 Million USD | -5.59% |
| 1989 Q2 | -17.9 Million USD | 38.91% |
| 1989 FY | -29.3 Million USD | -1.38% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bright Green Corporation | 1.84 Million USD | -930055.659% |
| Alpha Teknova, Inc. | 1.97 Million USD | -867726.748% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | -18084.318% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | -22756.438% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | -3835.098% |
| Cosmos Health Inc. | 8.59 Million USD | -199310.832% |
| Journey Medical Corporation | -9.7 Million USD | 176543.506% |
| Embecta Corp. | 1.31 Billion USD | -1205.709% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | -3634.671% |
| Dynavax Technologies Corporation | 106.63 Million USD | -15964.988% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 13194.115% |
| Pacira BioSciences, Inc. | 432.74 Million USD | -3858.65% |
| PainReform Ltd. | -7.95 Million USD | 215583.019% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 109670.146% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 109670.146% |
| SCYNEXIS, Inc. | -19.35 Million USD | 88631.783% |
| Safety Shot Inc | -2.28 Million USD | 750016.279% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 181769.002% |
| Procaps Group, S.A. | 242.93 Million USD | -6951.726% |
| Theratechnologies Inc. | 24.87 Million USD | -68779.016% |
| Harrow Health, Inc. | 116.41 Million USD | -14615.119% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 679897.619% |
| Biofrontera Inc. | 4.05 Million USD | -422259.467% |
| DURECT Corporation | -7.65 Million USD | 223916.305% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 51195.833% |
| Cronos Group Inc. | -663.32 Million USD | 2682.573% |
| OptiNose, Inc. | 58.06 Million USD | -29402.971% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | -2648.049% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 117660.39% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 330427.759% |
| Organogenesis Holdings Inc. | 15.01 Million USD | -114007.107% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 269468.767% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -16031212.29% |
| Radius Health, Inc. | 359.28 Million USD | -4668.106% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | -8686572.515% |
| ProPhase Labs, Inc. | 19.23 Million USD | -88979.611% |
| Phibro Animal Health Corporation | 454.84 Million USD | -3666.308% |
| Procaps Group S.A. | 242.93 Million USD | -6951.726% |
| Alvotech | 1.06 Billion USD | -1509.567% |
| TherapeuticsMD, Inc. | 3.67 Million USD | -465666.721% |
| Rockwell Medical, Inc. | 4.45 Million USD | -384345.691% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 351358.971% |
| SIGA Technologies, Inc. | -148.68 Million USD | 11621.851% |
| Tilray Brands, Inc. | 158.97 Million USD | -10675.71% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | -13953.471% |
| Shineco, Inc. | 29.29 Million USD | -58386.59% |
| PetIQ, Inc. | 351.93 Million USD | -4767.659% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 590529.954% |
| Incannex Healthcare Limited | -5.48 Million USD | 312422.698% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -9562.098% |
| Alimera Sciences, Inc. | 55.3 Million USD | -30873.079% |
| Silver Spike Investment Corp. | -32.61 Million USD | 52630.025% |
| Assertio Holdings, Inc. | -32.52 Million USD | 52763.47% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 1150811.819% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 338629.645% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | 355955.837% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 208670.621% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | -406134.29% |
| Hempacco Co., Inc. | 13.61 Million USD | -125726.681% |
| Talphera, Inc. | -5.72 Million USD | 299538.909% |
| Alvotech | 1.06 Billion USD | -1509.567% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | -239660.672% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 17813.68% |
| Currenc Group, Inc. | -16.57 Million USD | 103465.539% |
| Kamada Ltd. | -46.43 Million USD | 36994.98% |
| Indivior PLC | -33.95 Million USD | 50556.243% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | -6574193.675% |
| Flora Growth Corp. | -713 Thousand USD | 2402750.771% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 208670.621% |
| Evolus, Inc. | 63.7 Million USD | -26789.716% |
| HUTCHMED (China) Limited | -197.45 Million USD | 8775.718% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | -3475.56% |
| Akanda Corp. | 3.9 Million USD | -438600.858% |